วัน: 25 กรกฎาคม 2025

Starter Deck 03 ‘Ω to the Future’ marks the highly anticipated debut of Ultraman Omega in card form, featuring exclusive cards and brand new strategies that bring the latest TV series to life and allowing fans to experience the title hero’s journey.Booster Pack 04 ‘Gleam of Eternal Hope’ introduces powerful new versions of iconic Ultra Heroes including Ultraman Dyna, Z, and Trigger. These upgraded cards unlock expanded tactical possibilities, reshaping the game and delivering fresh competitive angles for seasoned players.With the release of both new sets as well as the return of fan-favourite ExP (Extra Parallel) rarity cards, and momentum building toward the Ultra League World Championship 2026, the Ultraman Card Game is poised to grow its global fanbase and strengthen its presence within the trading card game community.KUALA LUMPUR, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Tsuburaya Productions unveils today the latest additions to the ever-popular Ultraman Card Game - Starter Deck 03 ‘Ω to the Future’ and Booster Pack 04 ‘Gleam of Eternal Hope’, launching globally on Friday, 25 July 2025 and Friday, 1 August 2025 respectively. These upcoming game sets build on the momentum of the newly launched Ultraman Omega television series, as well as beloved characters such as Ultraman Arc, whilst introducing brand-new gameplay mechanics, evolution strategies and dynamic synergies centred around these iconic Ultra Heroes. Ultraman Omega Makes His First-Ever Card Game AppearanceA highlight of the new Starter Deck 03 ‘Ω to the Future’ is the much-anticipated debut of Ultraman Omega in card form. This new deck draws inspiration from the ongoing Ultraman Omega television series, which premiered in Japan earlier this month.Reflecting the show’s narrative, the deck features exclusive cards from the Ultraman Omega series, including the titular Ultraman Omega, Meteokaiju, and fan-favourite Giants of Light such as Ultraman Arc. These new cards introduce fresh gameplay mechanics that reward strategic thinking and foresight, from granting power boosts when fielding characters of the same type to enabling tactical card rotations that encourage smarter deck management. With these new mechanics and play styles, players can look forward to reliving key story moments and experiencing Ultraman Omega’s growth firsthand.As an added early-release bonus, players will also be able to receive a bonus pack of Booster Pack 04 ‘Gleam of Eternal Hope’ for every purchase of Starter Deck 03 ‘Ω to the Future’, offering fans an early taste of the upcoming expansion and even more ways to power up their decks.Fan-Favourite Heroes Return with Upgraded PowersBooster Pack 04 ‘Gleam of Eternal Hope’ continues to expand the strategic possibilities of the game, featuring powerful upgraded cards for popular Ultra Heroes including Ultraman Dyna, Ultraman Z, and Ultraman Trigger.These upgrades introduce new abilities that not only refresh existing decks but also deepen tactical options across competitive formats. With a more extensive card pool, players can look forward to more creative deckbuilding strategies that are sure to influence the current approach to gameplay.Collectors Rejoice: ExP (Extra Parallel) Cards Make a ReturnBack by popular demand, the ExP (Extra Parallel) rarity cards - first introduced in Booster Pack 02 ‘Vortex of Crimson and Azure’ - make a dazzling return in ‘Gleam of Eternal Hope’.These collector-favourite cards are known for their exclusive full-art illustrations, premium foil finish, and elegant gold framing. Scheduled to be revealed on Friday, 1 August 2025, ‘Gleam of Eternal Hope’ will see the addition of two brand-new types of ExP card, offering high visual appeal and collectability for long-time fans and new enthusiasts alike.Exclusive Box Topper: Alien Baltan The Space NinjaAdding to the excitement, each 24-pack box of ‘Gleam of Eternal Hope’ will include a special box topper card featuring Alien Baltan, one of the most iconic villains in Ultraman history.This unique card mirrors Baltan’s illusory powers, allowing an unlimited number of copies to be included in a single deck - a rare and rule-breaking mechanic. The artwork captures the classic scene of Baltan duplicating itself and unleashing its signature red freezing ray, leveraging nostalgia for long-term fans.Fans in Malaysia can look forward to purchasing the English-language Starter Deck 03 ‘Ω to the Future’ at MYR 46.00 and Booster Pack 04 ‘Gleam of Eternal Hope’ in either individual packs at MYR 18.00 or as a 24-pack box at MYR 432.00 at authorised hobby stores, major retailers, and online platforms.These releases are poised to equip both new and veteran Ultra Leaguers with competitive decks ahead of major events, including the upcoming inaugural Ultra League World Championship 2026, set to take place on 9 and 10 May 2026 in Tokyo, Japan. This prestigious tournament will see players from around the world battling through regional qualifiers for a shot at the title of world’s best Ultra Leaguer, with exclusive cards and gameplay accessories up for grabs. For more information on the Ultraman Card Game, please refer to https://ultraman-cardgame.com/page/my/top.About Tsuburaya ProductionsTsuburaya Productions is a global entertainment company providing content, products and services full of creativity and innovation. Since the airing of Ultra Q and Ultraman in 1966, the company has continued to create characters and stories that are loved by fans worldwide.TSUBURAYA PRODUCTIONS Official Global Site: https://tsuburaya-prod.com/Ultraman Card Game Official Website: https://ultraman-cardgame.com/About Ultraman Card Game​The Ultraman Card Game is a dynamic trading card game developed by Tsuburaya Productions, bringing the iconic Ultraman universe to life through strategic gameplay and collectible cards. Designed for fans of all ages, the game features high-quality artwork showcasing Ultraman's heroes, kaiju, and special moves, offering both engaging play and collectibility. With simultaneous releases in multiple languages across various regions, the Ultraman Card Game invites players around the world to explore the rich legacy of Ultraman, engage in epic battles, and grow their collections. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” or the “Group”, Stock Code: 1061.HK) is pleased to announce that (Zhuhai Essex Bio-Pharmaceutical Company Limited), an indirect wholly-owned subsidiary, has received approval from (National Medical Products Administration) for the registration and commercialisation of the multi-dose Diquafosol Sodium Eye Drops in the PRC.The Approved Product is a multi-dose eye drop formulation containing 3% diquafosol sodium (5ml:150mg), indicated for the treatment of dry eye syndromes such as conjunctival epithelium injury and tear abnormalities. The active pharmaceutical ingredient, diquafosol sodium, is a P2Y2 receptor agonist that acts on conjunctival tissues to promote the secretion of tears containing water and secretory mucins. It may also promote the expression of membrane-bound mucins on corneal epithelium. Boosting the lipid content in tears, it should quantitatively and qualitatively improve tear abnormalities and demonstrate efficacy in bringing the ocular surface condition closer to normal, and improve symptoms of dry eye and corneal epithelial damage.The Approved Product, together with the previously approved preservative-free unit-dose Diquafosol Sodium Eye Drops collectively, collectively provide more high-quality treatment options for patients in the PRC.  The approval will further enrich the Group’s ophthalmic product portfolio and strengthen its market position in ophthalmology segment.About Essex (Stock Code:1061.HK)Essex is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology.These products are marketed and sold through approximately 14,000 hospitals, supported by the Company’s 44 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, Essex maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications. Copyright 2025 ACN Newswire via SeaPRwire.com.

SHANGHAI, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the “Sellers”), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue.Everest Medicines, together with its controlling shareholder CBC Group and the placing agents, entered into a placing and subscription agreement for the sale of 22,561,000 shares at a purchase price of HK$69.70 per share, representing:- a discount of approximately 10.12% to the closing price of HK$77.55 per share on July 24, 2025.- a discount of approximately 4.98% to the average closing price of HK$73.35 per Share as quoted on the Stock Exchange for the five consecutive trading days immediately prior to and including the Last Trading Date.- a premium of 16.15% to the volume weighted average price of HK$60.01 per Share as quoted on the Stock Exchange for the thirty consecutive trading days immediately prior to the Last Trading Date and including the Last Trading Date.The gross proceeds from the Placing and Subscription are expected to be approximately HK$1,572.50 million, and the net proceeds (after deducting all related expenses, including commission and levies) will be approximately HK$1,553.39 million.Everest Medicines intends to use approximately 50% of the net proceeds (approximately HK$776.69 million) to support global research and development of pipeline products, approximately 40% (approximately HK$621.36 million) to commercialization efforts including the launch of new products, and 10% (approximately HK$155.34 million) to working capital and general corporate purposes.“This placement was well-received by several leading international long-only funds and was significantly oversubscribed, reflecting strong capital market confidence in Everest’s commercial execution capabilities and innovative R&D strengths,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “It also underscores investors’ endorsement of our long-term strategic vision. We will use the proceeds to accelerate the development of innovative pipelines and our proprietary AI+mRNA platform, while advancing the commercialization of our existing portfolio. With a strengthened capital base, we are poised to drive both commercialization and innovation, delivering greater value to patients and shareholders.”Everest has built an industry-leading, fully integrated, and localized AI+mRNA platform, enabling the development of multiple oncology and autoimmune disease programs, including EVM14, an off-the-shelf therapeutic mRNA cancer vaccine; EVM16, a personalized mRNA cancer vaccine; and an in vivo CAR-T program aimed at building a differentiated portfolio of precision immunotherapies.- The first patient has been dosed with Everest’s internally developed personalized mRNA cancer vaccine (PCV) EVM16 at Peking University Cancer Hospital in the investigator-initiated clinical trial (IIT). Early results showed strong immunogenicity and specific T-cell responses even at a low starting dose in advanced cancer patients.- The Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) vaccine, has been accepted by both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA), making it Everest's first mRNA cancer therapeutic vaccine to achieve dual IND submissions in both China and the United States. The first clinical batch of EVM14 was successfully released from Everest’s Jiashan manufacturing site on June 9, and is anticipated to be delivered to U.S. clinical centers by mid-August. This batch will support the clinical trials of EVM14 in both China and the United States (US).- Everest’s in vivo CAR-T program is founded upon its proprietary targeted LNP (tLNP) delivery system and has shown promising results in both humanized mouse models and non-human primates. It offers key advantages including off-the-shelf availability, lymphodepletion-free administration, and dose controllability.EVER001, a next-generation covalent reversible BTK inhibitor with global rights, is advancing through global multi-center clinical studies for glomerular diseases such as primary membranous nephropathy (pMN). Positive results from its Phase 1b/2a clinical trial demonstrated rapid onset, durable response, good tolerability, and oral convenience, offering strong potential to address unmet needs in renal disease treatment worldwide.NEFECON®, the first and only etiological treatment for IgA nephropathy (IgAN) full approved in China, the U.S., and Europe, continues to gain strong commercial traction in China following its inclusion in the National Reimbursement Drug List (NRDL), benefiting over 20,000 patients to date. Everest is also accelerating the development of its proprietary diagnostic test for Gd-IgA1 to build an integrated disease management ecosystem encompassing diagnosis, treatment, and long-term care.The New Drug Application (NDA) for Etrasimod (VELSIPITY®) has been accepted in Mainland China, with approval anticipated between late 2025 and early 2026. The NDA has also been accepted in South Korea. VELSIPITY® has been commercially launched in Macao SAR, Singapore and Hong Kong SAR in 2024. As Everest’s third commercialized product, VELSIPITY® has been officially approved by the Guangdong Provincial Medical Products Administration for adult patients with moderately to severely active UC. It is now available at medical institutions designated under the Connect Policy in the Greater Bay Area. In March 2025, Everest has launched the construction project at its Jiashan manufacturing site to support the local production for VELSIPITY®.Everest Medicines is accelerating the strategic advancement of its core pipeline and AI+mRNA technology platforms to further solidify its position as a leading innovative biopharmaceutical company in Asia.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2025 ACN Newswire via SeaPRwire.com.

- The implementation of streamlined approval procedures for Hong Kong- and Macao-registered proprietary Chinese medicines (“pCms”) by mainland China presents significant opportunities for Hong Kong companies to expand into the Greater Bay Area and other mainland market.- A unified and comprehensive registration system strengthens the quality control of Hong Kong's pCms, reinforcing confidence among other regulatory bodies and stakeholders.- Hong Kong's first Chinese medicine hospital will gradually commence operations by year end. This will help promote the popularity of Chinese medicine and pCms.HONG KONG, July 24, 2025 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (“HKTDC”) today released a report, "Challenges and Opportunities in Hong Kong's Proprietary Chinese Medicine Industry," that analyses the sector’s development, challenges, and export potential of Hong Kong’s pCm sector. With the completion of the transitional registration process for pCms in June this year, all pCms sold in Hong Kong now hold formal registration, marking a new era in the regulatory regime. The Chinese Medicine Hospital of Hong Kong is set to begin operations by late 2025 further popularising pCms. Additionally, mainland China has streamlined approval procedures for Hong Kong-registered traditional pCms, creating easier access to the mainland market.Hong Kong’s pCms enjoy a strong reputation, with streamlined registration procedures facilitating expansion into the Mainland marketHong Kong currently has approximately 2,000 companies involved in pCms and Chinese herbal medicine-related businesses, including import/export trade, manufacturing, wholesale and retail. Among these, some 264 enterprises are listed as local pCm manufacturers. The majority of pCms produced in Hong Kong are geared toward the consumer market. In 2024, Hong Kong’s pCm exports totaled HK$2.88 billion with 93% locally produced, setting the industry apart from re-export-driven sectors. Mainland China remains the largest export market, accounting for over 70% of exports, followed by Macao (20%), and ASEAN (6%).Wing Chu, Principal Economist (Greater China) of the HKTDC, stated: "Many Hong Kong proprietary Chinese medicines companies are eager to expand exports especially to the mainland market although pCm imports in mainland China are relatively small, with different pCms registration system and technical standards from those of Hong Kong. Notably, Hong Kong’s pCms are highly regarded in Southern China and overseas Chinese communities, and streamlined approval procedures in mainland China for traditional pCms of Hong Kong and Macao offer significant opportunities for Hong Kong businesses to expand into the Greater Bay Area and other mainland markets. Additionally, the rise of online shopping enables companies to leverage cross-border e-commerce platforms to access mainland and overseas markets, provided they comply with the corresponding regulatory requirements.”Comprehensive registration system drives standardisation of Chinese medicineThe report indicates that, in recent years, the HKSAR Government has actively promoted the development of Chinese medicine. Key initiatives include the establishment of the Chinese Medicine Council of Hong Kong to oversee the registration and management of pCms, and continuous support for Chinese medicine services in areas such as education, medical treatment, and scientific research. These efforts have enabled Hong Kong to cultivate professional Chinese medicine talent and promote the modernisation of Chinese medicine. Earlier this month, some 345 Hong Kong enterprises, including traders, registered a total of 8,244 pCms.The report states that a unified and comprehensive registration system enhances the quality control of Hong Kong's pCms, further increasing the confidence of other regulatory bodies and stakeholders in these products. Hong Kong's first Chinese medicine hospital is set to open in late 2025, providing comprehensive diagnostic and treatment services with Chinese medicine, which will drive the popularisation of Chinese medicine and pCms.In addition, Hong Kong pCm companies and local universities are committed to developing new pCms to further expand the market. Recently, the Centre for Chinese Herbal Medicine Drug Development at Hong Kong Baptist University (HKBU), funded by the Innovation and Technology Commission of HKSAR Government under the InnoHK Research Clusters, developed a novel drug, CDD-2101, for the treatment of chronic constipation. The innovation is based on previous pilot clinical studies and basic research on the traditional Chinese herbal formulation "MaZiRenWan”. For the first time, it has received authorisation for clinical research in the United States.Prof. BIAN Zhaoxiang, Director of the Centre for Chinese Herbal Medicine Drug Development and Associate Vice-President (Clinical Chinese Medicine) at HKBU, said: "Our goal is to collect sufficient safety and efficacy data to obtain FDA approval for CDD-2101 as a marketable new drug and successfully launch it in the United States. This represents not only a major breakthrough in the research and development of Chinese medicine in Hong Kong but also an important step in driving the standardisation and internationalisation of Chinese medicine.”Mainland market surpasses RMB450 billionMainland China, the world's largest pCm market valued at RMB450 billion, streamlined registration and approval procedures in 2021 for traditional pCms for external use being sold in Hong Kong and Macao. In January 2025, the National Medical Products Administration further simplified the approval process for traditional pCms for oral use, provided they have been in use in Hong Kong for more than 15 years and whose production processes comply with Good Manufacturing Practice (GMP) requirements. Relevant application materials and technical requirements were also released in April this year. The report notes that the implementation of the streamlined registration procedures opens a more convenient channel for Hong Kong companies to expand into the Greater Bay Area and other mainland markets.The recognition and acceptance of pCms differ across overseas regions. In many international markets, pCms are categorised and regulated as herbal medicines, health foods or dietary supplements. However, many Southeast Asian countries have specific, similar legal requirements for pCms, providing a clear pathway to enter these markets.The rapid growth of global e-commerce has created new sales channels for Hong Kong’s pCms through cross-border e-retail. For the mainland market, the report points out that certain pCms for external use, such as Chinese medicinal wines and cooling oils, have been incorporated in the Cross-border E-commerce Retail Import Commodity List, allowing relevant products to be sold to mainland China through cross-border e-commerce channels.In overseas markets, the e-commerce retail sector in ASEAN is experiencing significant growth, fueled by robust demand for herbal and health-related products in local markets. By adhering to local regulations, Hong Kong pCm enterprises can capitalise on additional business opportunities through online channels.Annual Chinese Medicine Conference to Share Latest Research FindingsTo foster the development of the Chinese medicine industry, the International Conference of the Modernization of Chinese Medicine & Health Products will be held at the Hong Kong Convention and Exhibition Centre from 15 to 16 August 2025. The conference is jointly organised by the Modernized Chinese Medicine International Association, the HKTDC and 10 scientific research institutions. During the event, 21 scholars and experts from medical schools, research institutions, pharmaceutical companies and organisations from mainland China, Hong Kong, Malaysia and Thailand will discuss the latest research progress in the prevention and treatment of tumors, inflammation, and cardiovascular and cerebrovascular diseases using traditional medicine. They will also present a number of related clinical research results and share successful cases. For more details, please visit: https://www.hktdc.com/event/icmcm/en.Report and photo download: https://bit.ly/45kCaXuThe HKTDC today released its research report, "Challenges and Opportunities in Hong Kong's Proprietary Chinese Medicine Industry." Pictured from left are Wing Chu, Principal Economist (Greater China Research Team) at the HKTDC, and Prof. Bian Zhaoxiang, Director of the Centre for Chinese Herbal Medicine Drug Development at Hong Kong Baptist UniversityWing Chu, Principal Economist (Greater China Research Team) at the HKTDC, pointed out that mainland China has streamlined the approval procedures for eligible traditional proprietary Chinese medicines from Hong Kong and Macao, providing more opportunities for Hong Kong businesses to expand into the Greater Bay Area and mainland marketsProf. Bian Zhaoxiang, Director of the Centre for Chinese Herbal Medicine Drug Development at HKBU, stated that the university’s earlier development of a novel drug for chronic constipation is based on an ancient Chinese herbal formulation and was authorised for clinical research in the United States for the first time. This marked an important step in driving the standardisation and internationalisation of Chinese medicineMedia EnquiriesOgilvy Public RelationsChole ChanTel: (852) 6809 6633Email: chloe.chan@ogilvy.comLeanne PokTel: (852) 9379 9694Email: leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley SoTel: (852) 2584 4049Email: stanley.hp.so@hktdc.orgSerena CheungTel: (852) 2584 4272Email: serena.hm.cheung@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 24, 2025 - (ACN Newswire via SeaPRwire.com) - Quantum Solutions Co.,Ltd. (2338.T), a Tokyo Stock Exchange-listed company, announced the official launch of its Bitcoin treasury initiative in 23rd July. Over the next 12 months, the company plans to gradually build a reserve position of up to 3,000 Bitcoins (BTC) as part of a broader long-term strategy to diversify its corporate treasury assets. The initiative will be managed and executed by its wholly owned Hong Kong subsidiary, GPT Pals Studio Limited, and will begin with an initial investment of USD 10 million provided by international investment firm Integrated Asset Management (Asia) Limited.This marks Quantum Solutions’ first public move into digital asset allocation. The company views Bitcoin as a long-term, strategic reserve instrument and will implement the plan in phases to ensure proper risk control and financial governance. The 3,000-BTC target will be pursued in stages, with procurement timing and scale subject to prevailing market conditions, capital availability, and regulatory context.Integrated Asset Management (Asia) is a Hong Kong-based investment company that led the acquisition of Forbes Media in 2014. The firm, founded by Tak Cheung Yam, specializes in public and private equity investments. Mr. Yam, through its controlled entities, including Integrated Asset Management (Asia), is a major shareholder of Forbes Media, with the Forbes family retaining a minority stake. Integrated Asset Management’s engagement in this initiative underscores a growing institutional openness toward incorporating Bitcoin within modern corporate treasury considerations.The operational responsibility for the Bitcoin reserve project lies with GPT Pals Studio Limited, which has begun establishing a secure and auditable digital asset infrastructure, including segregated cold and hot wallet systems, internal controls, and accounting mechanisms. The company’s board and audit committee will provide periodic oversight of the portfolio’s valuation, exposure, and governance, in accordance with applicable regulatory and accounting standards.At current market prices, the target reserve of 3,000 BTC would be equivalent to approximately JPY 53.8 billion (USD 350 million). The company clarified that this is a long-term positioning effort rather than a short-term speculative activity and that it intends to align asset deployment with financial stability and shareholder value.“We are uniquely positioned to build a Bitcoin-first capital structure. Our goal is not only to accumulate Bitcoin, but to do so with institutional-grade discipline,” said Francis Zhou, CEO of Quantum Solutions. “We are in advanced discussions with top-tier asset managers, sovereign wealth allocators, and fintech leaders to scale our treasury roadmap responsibly and rapidly.”Globally, an increasing number of public companies and institutional investors are adopting Bitcoin as a hedge against inflation and monetary policy risk. Quantum Solutions’ initiative places it among a growing group of companies taking early steps toward integrating blockchain-based assets into their financial frameworks. The decision to leverage Hong Kong as the operational base reflects confidence in the region’s infrastructure, policy clarity, and gateway role for global capital engagement.Tak Cheung Yam, founder of Integrated Asset Management Limited, shared his perspective on Quantum Solutions: "Quantum Solutions demonstrates a clear strategic vision and determination. I see compelling potential in their approach to building a significant Bitcoin treasury, and I look forward to supporting their efforts in unlocking institutional pathways and capital alignment. It's a timely opportunity for firms with global ambition and focused execution."This launch represents a significant development in Quantum Solutions’ broader capital strategy, transitioning from a traditional AI and tech solutions provider to an enterprise with a forward-looking, diversified financial architecture. The company will continue to explore ways to enhance its treasury structure by evaluating new asset classes and cross-border capital tools that strengthen its long-term balance sheet resilience.If the Bitcoin reserve program generates a material impact on the company’s financial performance in the future, disclosures will be made in accordance with Tokyo Stock Exchange regulations and financial reporting requirements.About Quantum Solutions Co., Ltd.Quantum Solutions Co., Ltd. (Tokyo Stock Exchange: 2338.T) is a Tokyo-based high-growth technology company specializing in artificial intelligence, big data analytics, and blockchain-related innovation. Founded in 2004 and listed on the Tokyo Stock Exchange, the company delivers advanced technology solutions across a range of industries, including fintech, healthcare, and smart manufacturing. In its financial year ended 28 February 2025, Quantum Solutions reported approximately USD 4.7 million in revenue and is currently holdings over several trademarks and patents in games. For more information, please visit: https://www.quantum-s.co.jp/en/corporate Forward-Looking StatementsThis press release contains forward-looking statements based on information currently available to the company and certain assumptions regarding future events and expectations. These statements are subject to various risks and uncertainties—including but not limited to changes in policy, market conditions, technological developments, and regulatory factors—that could cause actual results to differ materially from those expressed or implied in such statements. Existing and prospective investors are advised to consider potential risks carefully and not to place undue reliance on any forward-looking statements contained herein. Such statements speak only as of the date of this release. Unless required by law, the company undertakes no obligation to update or revise any forward-looking statements in light of new information, future events, or other circumstances.For further enquiries, please contact:Hong Kong/International:Mr. Steven TungEmail: steven.tung@quantum-s.co.jpJapan:Ms. Linda PengEmail: linda.peng@quantum-s.co.jp Copyright 2025 ACN Newswire via SeaPRwire.com.